{"id":"W3213271278","doi":"10.1182/blood-2021-154022","title":"Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Blinatumomab; Medicine; Minimal residual disease; Internal medicine; Rituximab; Cytarabine; Oncology; Chemotherapy; Acute lymphocytic leukemia; Maintenance therapy; Gastroenterology; Leukemia; Immunology; Pediatrics; Lymphoblastic Leukemia; Lymphoma","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002339525,0.0006399015,0.001306864,0.0004458581,0.0001582619,0.00004717564,0.0004159941,0.0002780696,0.0001693764],"category_scores_gemma":[0.0004805633,0.0004935818,0.0001102054,0.002178332,0.0003330036,0.0002566833,0.0003682876,0.0007118803,0.00002906405],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009684065,"about_ca_system_score_gemma":0.005987621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003482941,"about_ca_topic_score_gemma":0.002229356,"domain_scores_codex":[0.9947612,0.0003059674,0.001071945,0.001421499,0.001563547,0.0008758707],"domain_scores_gemma":[0.9962819,0.0006838964,0.0004523275,0.00122594,0.0008851432,0.0004707914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2539646,0.1877315,0.01293097,0.0008755205,0.01039797,0.1994607,0.05670035,0.002025824,0.270524,0.00002350468,0.00332826,0.002036765],"study_design_scores_gemma":[0.7102143,0.03506694,0.006388615,0.002044857,0.003079722,0.0009877369,0.007871908,0.004059222,0.2293711,0.00001764698,0.00006681946,0.0008310751],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957099,0.0001395883,0.00006490361,0.0003396667,0.00007549408,0.001974582,0.0009498079,0.0001184052,0.0006276586],"genre_scores_gemma":[0.9958392,0.00005369328,0.001989458,0.0001188824,0.0002117801,0.0001745664,0.001198247,0.0001322262,0.0002819043],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4562497,"threshold_uncertainty_score":0.9997516,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01257834677322908,"score_gpt":0.2672741256543651,"score_spread":0.254695778881136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}